UNSPSC 51123005: Hydroquinidine

This classification denotes an anti-arrhythmia agent and parasympatholytic with the molecular formula C20H26N2O2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 6BR4G8VAHM, chemically known as hydroquinine, hydrochloride but more generally known as hydroquinidine hydrochloride, which bears US NIH Compound Identifier 102134. European Medicines Agency schedules Hydroquinidine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14137MIG.

As of Q4 2014, HYDROQUINIDINE remains US FDA's Preferred Term for this commodity. SMILES: CCC1CN2CCC1CC2C(C3=C4C=C(C=CC4=NC=C3)OC)O.CL.

UNSPSC 51123005 Hydroquinidine is a Commodity code that represents a single active pharmaceutical ingredient used in emergency cardiac medications and advanced life support protocols, as evidenced by state and local procurement activity focused on supplying finished-form emergency medications rather than bulk chemical hydroquinidine itself. State and local governments procure under this code primarily through fire-rescue departments, health agencies, and pharmacy benefit programs that require Advanced Life Support Medications for emergency response and patient care. The actual buying pattern reflects procurement of multi-drug medication kits and generic pharmaceutical line items by emergency medical services, state health and human services commissions, and cooperative purchasing alliances supporting regional healthcare networks. Issuing bodies include city fire-rescue departments (Tampa Fire Rescue through the City of Tampa Purchasing Department), state health agencies (Texas Health and Human Services Commission), and multistate cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance serving participating state and local government facilities across multiple states including Oregon).

Geographic activity spans Florida, Texas, Minnesota, and Oregon based on recent posted opportunities. The City of Tampa issued an IFB (Bid No. 26-P-00188) for Advanced Life Support Medications with a response deadline of April 8, 2026, and an estimated contract value of $40,000.00, requiring supply of Labetalol HCl, Epinephrine, Adenosine, and Diltiazem vials with nine-month minimum expiration dates, firm pricing including all freight to Tampa, and delivery within ten calendar days; this opportunity included a 5 percent Small Local Business Enterprise bid discount not to exceed $10,000. The Texas Health and Human Services Commission posted RFI No. HHS0017013 on April 3, 2026, to solicit vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking direct contracting experience outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Department of Administration's Office of State Procurement, administering MMCAP, issued an RFP (Solicitation S1070000015802) with a March 26, 2026, response deadline for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) with contract effectiveness on July 1, 2026, and pricing evaluation weighted 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and administrative fee agreement.